Background: Inflammatory bowel disease [IBD] is considered to result from the interplay between host and intestinal microbiota but its pathogenesis is incompletely understood. While IBD in adults has shown to be associated with marked changes in body fluid metabolomics, there are only few studies in children. Hence, this prospective study addressed the faecal and serum metabolomics in newly diagnosed paediatric IBD. Methods: Paediatric patients with IBD undergoing diagnostic endoscopies and controls also with endoscopy but no signs of inflammation provided blood and stool samples in a tertiary care hospital. Blood inflammatory markers and faecal calprotectin levels were determined. The serum and faecal metabolomics were determined using ultra-high pressure liquid chromatography coupled to a mass spectrometer. Results: Serum and faecal metabolite profiles in newly diagnosed paediatric IBD patients were different from healthy controls and categorized Crohn's disease and ulcerative colitis [UC] patients into separate groups. In serum, amino acid metabolism, folate biosynthesis and signalling pathways were perturbed in Crohn's disease; in UC also sphingolipid metabolic pathways were perturbed when compared to controls. In faecal samples, there was an increased level of several metabolites in UC in contrast to low or intermediate levels in Crohn's disease. There was a clear correlation with the level of inflammation, i.e. faecal calprotectin levels and the profile of various biologically important metabolites [carnosine, ribose and, most significantly, choline]. Conclusion: Characterization of inflammatory pattern using metabolomics analysis is a promising tool for better understanding disease pathogenesis of paediatric IBD.
Introduction
Recent decades have seen a dramatic increase in inflammatory bowel disease [IBD] , in adult and paediatric patients alike. The reasons for this increase, however, remain unknown, although likely causes may include the Western lifestyle, excessively good hygiene, intake of antibiotics and specific diets. [1] [2] [3] Diagnoses of IBD always include chronic inflammation of the gastrointestinal tract with the exclusion of other causes of inflammation. IBD is divided into three different subtypes: Crohn's disease, ulcerative colitis [UC] and unclassified IBD [IBDU] . These subtypes differ in patterns of involvement and development. 4 IBD is attributed to a dysregulated immune response towards the intestinal microbiota in genetically predisposed individuals. In children, IBD tends to be more extensive and aggressive compared to adult counterparts, the reasons for these differences being far from clear. 5 It has been well established that changes in microbiota affect the immune system and metabolic pathways. These changes are of great interest also in IBD research as they may develop into markers indicative of the onset of the disease or into markers guiding treatment. This can be illustrated by recent findings on microbial patterns related to paediatric Crohn's disease as well as segmentation of responders to anti-tumour necrosis factor [TNF] treatments in paediatric IBD. 6, 7 Another way to detect microbial changes is to use unsupervised metabolomics approaches. These aim to reveal metabolite perturbations associated with diseases by measuring high sample throughput of multiple metabolites in biological samples, such as blood and faeces. [8] [9] [10] Recent findings in a worldwide IBD study show that the metabolite profiles can be powerful in stratifying patients according to their disease subtype [UC or Crohn's disease]. 11, 12 Specifically in view of the high treatment costs and severity of the disease, there is an urgent need to manage a more individual treatment for patients than currently is practical. Whether metabolite profiles may aid in guiding an individual treatment is an unanswered question. 12, 13 The few reported studies using metabolomics in IBD comprise only adult patients and do not include newly diagnosed patients. Hence, we focused in this study on applying a metabolomics approach to newly diagnosed paediatric IBD patients, who are known to display unique characteristics and disease development. We show that both blood and faecal metabolites can be used to classify Crohn's disease and UC patients and separate them from healthy subjects, providing new options for diagnostics and treatment.
Subjects and Methods
We invited 6-to 17-year-old native Finnish patients with IBD treated at the Gastroenterology unit of the Children's hospital, Helsinki University, Finland, to this prospective study on metabolomics. All IBD diagnoses were endoscopy-based and fulfilled the revised Porto criteria. 4 Controls [n=29] were patients undergoing endoscopy because of abdominal pain [n=13], haematochezia [n=5], diarrhoea [n=4] and for other reasons [n=7] to exclude IBD. None of these control subjects presented with active inflammation. All participants were requested to provide a blood sample and a stool sample for study purposes. All blood samples were taken when starting preparations for the anaesthesia. Thus, all patients and controls were fasting when sampled and had undergone a similar procedure for bowel cleansing. Faecal samples were taken at home within 2 days before admission or on the ward before starting bowel cleansing. Secondly, after analysing the first sample set of patients undergoing diagnostic investigations, we invited 12 of the included patients [n=51] to provide a follow-up sample once while recruiting additional patients undergoing diagnostic investigations for IBD [n=18; validation cohort]. These samples comprised the second sample set; in total 69 patients were included [ 14 For most of the analyses, the groups of 's disease  26  10  6  Ileocolonic  6  4  1  Colonic  7  2  2  Ileal  12  3  3  Perianal only  1  1  0  Colitis ulcerosa  15  5  3  Extensive colitis  12  4  3  Left-sided colitis  3  0  0  Proctitis  0  1  0  Unclassified IBD  10  3  3  Extensive colitis  6  2  3  Left-sided colitis  4  0  0  Proctitis  0  1 
Metabolomics analyses
All samples were analysed in a double random order, i.e. first step at the metabolite extraction phase and the second step at the liquid chromatography [LC] injection order. Investigators were blinded to the patient classification information when performing the sample analyses. [FA] was added to the sample and homogenized for three cycles of 30 s each at 5500 r.p.m. with a 10-s pause between each homogenization interval. After homogenization, the sample tubes were centrifuged for 15 min at 8000 g at 4 °C and the supernatant was collected in a 1.5 ml Eppendorf tube. In the second step, 10 parts of 80:20% ACN/H 2 O + 1% FA was added to the remaining pellet, the steps as detailed above were repeated, and finally the pellet was pooled to the previous extract and the whole extract centrifuged again for 15 min at 14 000 g at 4 °C. A dilution set of 1:50 was made to quantify the highly abundant metabolites.
Faecal sample extraction

Serum sample extraction
Ten microlitres of labelled internal standard mixture was added to 100 µl of serum sample. Metabolites were extracted by adding four parts [1 : 4, sample/extraction solvent] of the 100% ACN + 1% FA solvent.
The collected extracts were dispensed in Ostro™ 96-well plates [Waters Corporation] and filtered by applying vacuum at a delta pressure of 300-400 mbar for 2.5 min on the robot's vacuum station. This resulted in a cleaner extract to the 96-well collection plate, which was placed under the Ostro plate. The collection plate was sealed with the cap map and centrifuged for 15 min at 5000 r.p.m. at 4 °C and then placed in auto-sampler of the LC system for the injection.
Instrumentation and analytical conditions
Sample analysis was performed on an ACQUITY ultra pressure liquid chromatography tandem mass spectrometry [UPLC-MS/MS] system [Waters Corporation] and the detection system, a Xevo® TQ-S tandem triple quadrupole mass spectrometer [Waters] , was operated in both positive and negative polarities. A detailed description of the analytical conditions is given elsewhere. 17 All the measured metabolites with corresponding multiple reaction monitoring [MRM] conditions are given in Supplementary Table S1.
Metabolomics data analysis
Metabolomics data analysis was carried out using a web-based comprehensive metabolomics data processing tool, MetaboAnalyst 3.0 [http://www.metaboanalyst.ca]. 18, 19 Hierarchical cluster analysis was performed in order to identify clustering patterns while Pearson's correlation coefficient was used to evaluate the correlation between each pair of features. For these purposes, each variable of the quantitative data was first normalized by the median value of the control group and then log-transformed. Dendrograms were plotted on pre-processed data using Ward's linkage clustering algorithm and Pearson's correlation similarity measure. Dendrograms were visualized through heatmaps, where each coloured cell on the map corresponds to a concentration value. To analyse differences among groups, univariate analyses and t-tests were performed on pre-processed data. To explain the maximum separation among groups, unsupervised and supervised multivariate regression techniques, principal component analysis [PCA] and partial least squares discriminant analysis [PLS-DA], respectively, were performed. For each model, the optimal number of components was chosen according to the highest prediction accuracy estimated by the 5-fold crossvalidation technique. Sensitivity, specificity and receiver operating characteristic [ROC] statistics were also computed. To validate the model, accuracy in predicting group labels in the second sample set [fresh diagnosis] was measured. Variable importance in projection [VIP] is one of the important measures of PLS-DA, and is a weighted sum of squares of the PLS loadings taking into account the amount of explained class variation in each dimension. Metabolites were ranked according to their VIP scores and usually metabolites with VIP scores greater than 1 are considered as the most significant contributors. To identify biologically meaningful patterns based on the metabolomics data, quantitative enrichment analysis [QEA] was carried out. Data were mapped to the human metabolome database, where the 'metabolic pathway associated metabolite sets' library comprising 88 metabolite sets of normal metabolic pathways was chosen for QEA. All the mapped metabolic pathways with total number of metabolites and matched metabolites from the data are given in Supplementary Table S2 .
Results
A total of 69 IBD patients and 29 controls were enrolled in this study [ Table 1 ]. All patients with IBD included in the first sample set were undergoing diagnostic endoscopies. The control group comprised patients with no signs of intestinal inflammation in the intestinal biopsies. The second sample set consisted of 12 follow-up samples available from first sample set [Crohn's n=6, UC/IBDU n=6], and additional samples from 18 newly diagnosed patients [no medication, Crohn's n=10, UC/IBDU n=8] as a validation cohort. All subjects provided blood samples and a subset donated faecal samples, which are difficult to obtain from this age group. The major results below are presented for the first sample set, with the findings of the second sample set commented upon separately later.
For the first sample set, the whole metabolomics profiles are shown as heatmaps for serum samples [ Figure 1A ] and faecal samples [ Figure 1B ], where distinct metabolite profiles were observed in faecal rather than serum samples. The key metabolites that contributed most to the separation between controls, Crohn's disease and UC are shown in a PLS-DA VIP plot, ranking these by importance [ Figure 2 ]. In serum, neopterin showed as a top metabolite in the discriminant analysis with higher levels in Crohn's disease, lower levels in controls and intermediate levels in UC. The following top metabolites that are involved in the urea cycle, arginine and methionine metabolisms, namely L-arginine, dimethylglycine, asymmetric dimethylarginine, guanosine, L-octanoylcarnitine, betaine, L-cystathionine, citrulline and decanoylcarnitine, also showed similar profiles, i.e. higher in Crohn's and UC being in between Crohn's and controls. Glycocholic acid, L-isoleucine, symmetric dimethylarginine, serine, phosphoethanolamine, proline and hexanoylcarnitine, by contrast, showed higher values in UC, lower values in controls and intermediate values in Crohn's. L-Tryptophan, kynurenic acid and trimethylamine-N-oxide showed lower values in the disease groups [ Figure 2A ]. Unlike serum samples, metabolomic analyses of faecal samples clearly showed elevated levels of all the top metabolites, except cytosine, in UC as compared to Crohn's disease and controls [ Figure 2B ]. PLS-DA cross-validation summaries are shown in Supplementary Figure S1A for serum and Figure S1B for faecal samples. The faecal metabolomics profile, even with 37 samples, was superior to the serum metabolomics profile, with 79 samples, in discriminating the controls and the two disease subtypes, and between the two disease subtypes. The performance of the chosen PLS-DA model is shown in Supplementary Table S3 for controls and disease groups.
To identify biologically meaningful patterns based on the metabolomics data, QEA was done separately for Crohn's disease and UC in both serum and faecal samples. In Crohn's disease, metabolic pathway analysis in serum depicted folate and pterine biosynthesis, purine, amino acid, betaine, nicotinate and nicotineamide metabolisms, urea cycle and intracellular signalling pathways as significantly enriched compared to controls [ Figure 3A ]. In UC, most of the metabolic pathways, except signalling pathways, were perturbed in addition to bile acid biosynthesis and sphingolipid metabolisms when compared to controls [ Figure 3B ]. In faecal samples, no pathways were significantly altered in Crohn's disease [data not shown], whereas in faecal samples of UC patients, the majority of the studied pathways were perturbed when compared to controls, taurine and hypotaurine metabolism being the most highly enriched pathways [ Figure 3C ].
We further investigated the metabolite differentiations localized to colitis in both Crohn's disease and UC. Interestingly, when UC/IBDU patients [25 serum samples and ten faecal samples] were compared to patients with Crohn's colitis [13 serum samples and seven fecal samples; patients with ileal disease excluded], we found increased levels of normetanephrine, propionylcarnitine, deoxycytidine, allantoin and spermidine in serum UC samples, and L-asparagine, L-aspartic acid, 5-hydroxy-L-tryptophan, guanosine, L-serine, L-glutamine, L-arginine and L-threonine in faecal UC samples. Conversely, we found decreased levels of inosine, guanosine, adenosine, cytosine, AMP, sorbitol and arginine in serum UC samples [ Figure 4A ], and pyridoxine, pyridoxic acid, orotic acid and kynurenic acid in faecal UC samples [ Figure 4B ]. At pathway level, purine metabolism and oxidation of branched chain fatty acids were perturbed in serum samples [ Figure 4C ]. In faecal samples, amino acid metabolisms, malate-aspartate shuttle, ammonia recycling, urea cycle and glucose-alanine cycle were perturbed [ Figure 4D ]. As expected in this cohort of adolescents, we observed some gender differences in metabolite patters, while UC faecal metabolic profiles were more clearly separated from controls in girls than in boys [Supplementary Figure S2A pattern with ESR and serum metabolites was different from UC [ Table 3 ]. Having established that the metabolomics approach is instrumental in differentiating Crohn's disease and UC patients as well as controls, we wanted to validate these findings in a series of newly diagnosed IBD patients. In this second sample set with ten Crohn's disease and eight UC/IBDU patients, we observed essentially similar results as in the first sample set, i.e. no striking differences in serum metabolomics profiles but similar differentiating patters when faecal metabolites were compared. Most of the significantly altered faecal metabolites showed an almost similar profile in both the first dataset and the second validation dataset. This clearly shows the robustness of the method and repeatability of the results. The performance of the chosen PLS-DA model in this second sample set is shown in Supplementary Table S4.
We had the opportunity to analyse the follow-up samples of 12 UC/IBDU and Crohn's study participants. We observed interesting features even in these limited longitudinal follow-up samples. When serum follow-up samples were compared to the samples obtained at the time of diagnosis [reflecting higher disease activity], the top ranked metabolites in the PLS-DA VIP analysis showed higher levels in Crohn's disease compared to UC at baseline, but opposite profiles [i.e. elevated levels declined in the latter or vice versa] were observed at follow-up, i.e. all the other most important metabolites except for adenosine and inosinic acid were decreased in Crohn's disease [Supplementary Figure S3A] . Similarly, in faecal samples, baseline metabolite profiles had elevated levels in UC compared to Crohn's, whereas half of the top ranked metabolite levels were reduced in follow-up UC faecal samples [Supplementary Figure S3B] . 
Discussion
To the best of our knowledge, this is the first published report on metabolomics in paediatric IBD with newly diagnosed patients. We found significantly different metabolite profiles in paediatric UC and Crohn's disease patients compared to healthy controls. In serum samples, amino acid metabolism, folate biosynthesis and signalling pathways were perturbed in Crohn's disease while sphingolipid metabolic pathways were also perturbed in UC compared to controls. In faecal samples, we found that Crohn's disease patients showed in general low or intermediate levels of metabolites that were more abundantly present in paediatric UC. In addition, faecal metabolite profiles stratified Crohn's disease and UC into separate groups better than serum samples. In faecal samples, most of the metabolic pathways were perturbed in UC, contrasting with Crohn's disease with none of the metabolic pathways perturbed. The key players in metabolic pathways depicted here probably include liver metabolism, especially for the serum metabolites, and microbial metabolism for the faecal samples, although this needs additional study.
In serum, neopterin showed as a top metabolite in the discriminant analysis between paediatric IBD patients and controls. Also, when related to the level of inflammation, the metabolites showing strong correlation to blood inflammatory markers included neopterin, an intermediate metabolite in the synthetic pathway of biopterin. Previously, faecal neopterin has been indicated as an inflammatory marker of Crohn's disease or UC, 22, 23 but was not depicted here among the major metabolites in faecal samples. It has been suggested that serum neopterin levels originate from activated T cells induced by interferon-γ [as a metabolite of guanosine monophosphate] and are not significantly different in active or quiescent disease. 23 It is notable, however, that in paediatric IBD a significant proportion of the patients may have low levels of inflammatory markers, namely ESR or C-reactive protein, despite active disease. 24 Thus, when related to these inflammatory markers the measurement of serum metabolites may bring little information in most patients. The relation between faecal calprotectin, a surrogate marker of intestinal inflammation, and faecal metabolites depicted carnosine, choline and taurine as the most significant metabolites associating with the level of inflammation. L-carnosine may protect against colonic mucosal injury through induction of heat shock protein 72 and suppression of NF-kappaB activation, as suggested in an experimental study in rats. 25 Also, this dietary dipeptide may down-regulate the intestinal inflammatory response by inhibiting in intestinal epithelial cells interleukin-8 secretion that is stimulated by, for example, TNFα. 26 Faecal metabolomics may also reflect microbial and mucus metabolism in the gut. Recently, it was suggested that trimethylamine-N-oxide [TMAO], which is generated by gastrointestinal anaerobes through the digestion of dietary phosphatidylcholine and carnitine in a microbial-mammalian co-metabolic pathway, might serve as a biomarker for IBD. 27 Interestingly, hippurate has been linked to the presence of Clostridia in the gut, 12 the relative abundance of these bacteria being tightly associated with the level of intestinal inflammation 7 while they are depleted in UC patients. 28 Furthermore, in Crohn's disease the down-regulation of hippurate is considered to result from altered gut microbial metabolism. 13, 29 However, hippurate also allows discrimination between lean and obese subjects. Unexpectedly, hippurate was not among our top list of disease-related metabolites. One explanation underlying the observed differences might be variation in the diet of the subjects in different studies. Unfortunately, specific data on dietary records were not available. Most patients in our study were undergoing diagnostic evaluation for IBD and with few exceptions were treatment naïve at the time of delivering the samples. Thus, the observed differences were not related to ongoing medications. Most patients had moderate or severe disease activity, and thus the major findings reflect state of active disease. Intriguingly, a recent study conducted in young patients with type 1 diabetes suggested that alterations in lipid and amino acid metabolism might precede the development of autoimmunity. The authors speculated that autoimmunity might develop as a response to metabolic alterations 30 indicated not only in humans but also in serum metabolomics in mice. 31 In keeping with this, a recent report on mice suggested that immune cell infiltration precedes lipid accumulation, leading to an altered lipid membrane 32 Recently, N-acetylated compounds, phenylalanine, and low-[LDL] and very low-density lipoprotein [VLDL] particles were suggested as candidate markers for stratification of adult IBD patients in remission or with active disease. 13 However, they could not clearly separate patients with Crohn's disease and UC while we found serum neopterin, bile acids and amino acids as the differentiating metabolites but did not determine LDL and VLDL particles. In line with our findings, succinate and creatine were included among the metabolites as biomarkers for active disease. The method used by Dawiskiba et al. was proton nuclear magnetic resonance spectroscopy. 13 We observed an association between faecal calprotectin and metabolite profiles while allantoin and gamma-glutamylcysteine showed up as biomarkers for Crohn's disease, and aminoadipic acid, carnosine and ribose-5-phosphate for UC. Intriguingly, a recent spectroscopy-based study on adult IBD patients reported that for stratification of Crohn's disease and UC, the metabolites holding differential power primarily belonged to a range of amino acids, microbiota-related short chain fatty acids and lactate, suggesting an inflammation-driven malabsorption and dysbiosis of the normal bacterial ecology. 11 Unlike our paediatric patients, all the adult patients were on maintenance medication, at least partially modifying the observed results.
Gender and BMI
In faecal heatmap and PCA, girls with UC separated more clearly than boys from controls and Crohn's disease patients. In serum there was no such difference. The majority of patients we included were in midpuberty [aged 13-14 years] and we did not include infants. The pattern of pubertal development, e.g. the timing of growth spurt, is different between boys and girls and might in part explain the observed variation in metabolites. Unfortunately, the pubertal staging was not registered accurately enough to allow further analyses. As described previously, BMI is likely to be associated with the total metabolomic profile. Here, such correlations were rare in UC but in Crohn's disease amino acids and as expected creatinine were associated with BMI, also most likely reflecting diet as a driver. Also, depletion in serum amino acids may act as an indicator of impaired growth but the current dataset did not allow further analyses on this aspect.
The strength of the study is that the major patient cohort included treatment naïve patients. Also, all samples [with the exception of follow-up samples] were obtained in conjunction with thorough endoscopic investigations, i.e. the presence of intestinal inflammation was objectively verified. Furthermore, the likely differences in the diet between patients and controls were of lesser impact as both groups underwent a similar bowel cleansing procedure before blood sampling. Also, all samples were frozen without any delays and were well preserved at −70 °C until further metabolomics analyses. The targeted metabolite profiling was done using a good quality control were run to check their response. Data were processed manually by checking the quality of every peak in the samples, calibration samples and QC samples. Data were quantified using internal labelled standards and external calibration curves. As a limitation, the number of patients analysed was limited especially during follow-up, not allowing any further conclusions of metabolomic profiles at diagnosis related to disease outcome. This is further hampered by the fact that the disease characteristics are heterogeneous, resulting in low numbers of patients in various disease subgroups with a variable extent of inflammation. Taken together, paediatric IBD is a complex disease with various disease subgroups, and outcome ranges from mild disease course to aggressive phenotype in a significant proportion of patients. The pathogenesis of the disease is incompletely understood. Characterization of metabolomic patterns, especially in faecal samples, is a promising means for stratification of the disease subtypes. Whether the faecal metabolomic profile in active inflammation is tightly linked to the profiles of the intestinal microbiome 33 warrants future studies.
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